% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Forster:144833,
author = {T. Forster and S. Akbaba and D. Schmitt and D. Krug and R.
El Shafie and J. Oelmann-Avendano and K. Lindel and L.
König and N. Arians and D. Bernhardt and F. Marmé$^*$ and
A. Schneeweiss and J. Heil and C. Sohn and J. Debus$^*$ and
J. Hörner-Rieber$^*$},
title = {{S}econd breast conserving therapy after ipsilateral breast
tumor recurrence - a 10-year experience of re-irradiation.},
journal = {Journal of contemporary brachytherapy},
volume = {11},
number = {4},
issn = {1689-832X},
address = {Poznań},
publisher = {Termedia},
reportid = {DKFZ-2019-02258},
pages = {312 - 319},
year = {2019},
abstract = {The aim of this study is to evaluate the efficacy and
toxicity of post-operative partial breast re-irradiation
with multi-catheter brachytherapy after second breast
conserving therapy (BCT) in patients with small, low-risk
ipsilateral breast tumor recurrence (IBTR).Between 2008 and
2018, 19 consecutive patients with low-risk IBTR (max. rpT1
cN0 cM0, Her2 negative, preferably positive hormone receptor
status) who refused mastectomy were treated with salvage
lumpectomy, followed by post-operative partial breast
re-irradiation with multi-catheter brachytherapy. Eight
patients were irradiated using PDR brachytherapy (49.8-50.4
Gy in pulses of 0.5-0.7 Gy) and 11 patients using HDR
brachytherapy (34.2 Gy in fractions of 3.8 Gy or 32 Gy in
fractions of 4 Gy). All patients had undergone prior BCT for
their primary tumor, followed by adjuvant whole breast
radiotherapy. Local control (LC), locoregional control
(LRC), overall survival (OS), disease-free survival (DFS) as
well as toxicity were evaluated in the present study.After a
median follow-up of 65 months following IBTR (18-120
months), only one second IBTR in 19 patients was diagnosed
77 months after re-irradiation, resulting in a LC rate of
$100\%$ at 5 years. DFS and OS rates were both $100\%$ at 5
years following re-irradiation. Except for the above
mentioned second IBTR, no regional or distant relapse was
recorded. Regarding toxicity, $63\%$ of patients developed
adverse events (CTCAE grade ≤ 2), with fibrosis detected
in $37\%$ (7/19) of patients, necrosis in $11\%$ (2/19),
hyperpigmentation in $47\%$ (9/19), and telangiectasia in
$11\%$ (2/19), respectively. No patient showed a high-grade
(CTCAE grade ≥ 3) adverse event.In case of small, low-risk
IBTR, adjuvant re-irradiation using multi-catheter
brachytherapy is a feasible, safe, and effective treatment
method after repeated lumpectomy, and an alternative to
mastectomy.},
cin = {E050 / L101},
ddc = {610},
cid = {I:(DE-He78)E050-20160331 / I:(DE-He78)L101-20160331},
pnm = {315 - Imaging and radiooncology (POF3-315)},
pid = {G:(DE-HGF)POF3-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31523231},
pmc = {pmc:PMC6737570},
doi = {10.5114/jcb.2019.87001},
url = {https://inrepo02.dkfz.de/record/144833},
}